Docetaxel/capecitabine well tolerated but less effective than docetaxel/estramustine
Publication
, Journal Article
George, DJ; Moul, JW
Published in: Oncology Report
March 1, 2005
Duke Scholars
Published In
Oncology Report
ISSN
1548-5323
Publication Date
March 1, 2005
Issue
SPRING
Start / End Page
54 / 55
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
George, D. J., & Moul, J. W. (2005). Docetaxel/capecitabine well tolerated but less effective than docetaxel/estramustine. Oncology Report, (SPRING), 54–55.
George, D. J., and J. W. Moul. “Docetaxel/capecitabine well tolerated but less effective than docetaxel/estramustine.” Oncology Report, no. SPRING (March 1, 2005): 54–55.
George DJ, Moul JW. Docetaxel/capecitabine well tolerated but less effective than docetaxel/estramustine. Oncology Report. 2005 Mar 1;(SPRING):54–5.
George, D. J., and J. W. Moul. “Docetaxel/capecitabine well tolerated but less effective than docetaxel/estramustine.” Oncology Report, no. SPRING, Mar. 2005, pp. 54–55.
George DJ, Moul JW. Docetaxel/capecitabine well tolerated but less effective than docetaxel/estramustine. Oncology Report. 2005 Mar 1;(SPRING):54–55.
Published In
Oncology Report
ISSN
1548-5323
Publication Date
March 1, 2005
Issue
SPRING
Start / End Page
54 / 55
Related Subject Headings
- Oncology & Carcinogenesis